8-K: Syndax Q3 2025: Revenue Growth, Revuforj Approval

Syndax Pharmaceuticals announced strong third-quarter 2025 financial results, driven by significant revenue growth from its cancer therapies Revuforj and Niktimvo, alongside a key FDA approval for Revuforj.

Summary

• Total revenue for the third quarter of 2025 was $45.9 million, representing 21% growth over the second quarter of 2025.
• Revuforj net revenue reached $32.0 million, a 12% increase over the second quarter, with total prescriptions growing 25% to approximately 850.
• Niktimvo net revenue, reported by partner Incyte, was $45.8 million, a 27% increase over the second quarter, contributing $13.9 million in collaboration revenue to Syndax.
• Revuforj received U.S. FDA approval on October 24, 2025, for the treatment of R/R acute myeloid leukemia (AML) with a susceptible NPM1 mutation.
• The company's cash, cash equivalents, and investments stood at $456.1 million as of September 30, 2025, and are expected to fund operations to profitability.
• Net loss attributable to common stockholders for the quarter was $60.7 million, or $0.70 per share, an improvement from $84.1 million, or $0.98 per share, in the comparable prior year period.
• Research and development expenses decreased to $56.3 million from $71.0 million in Q3 2024, primarily due to a prior year milestone payment and completion of a registrational trial.
• Selling, general and administrative expenses increased to $44.9 million from $31.1 million, driven by commercial launch activities for Revuforj and Niktimvo.
• Full year 2025 guidance for total R&D plus SG&A expenses is $380 to $385 million, excluding an estimated $45 million in non-cash stock compensation expense.

Sentiment

Score: 8

Explanation: The company demonstrated strong commercial execution with significant revenue growth for both key products, achieved a critical FDA approval expanding market opportunity, and reduced its net loss while maintaining a strong cash position with a clear path to profitability. The robust pipeline and positive clinical data further enhance the positive outlook.

Positives

• Total revenue grew 21% quarter-over-quarter to $45.9 million, demonstrating strong commercial momentum.
• Revuforj net revenue increased 12% quarter-over-quarter to $32.0 million, with total prescriptions rising 25% quarter-over-quarter to approximately 850.
• Niktimvo net revenue (reported by Incyte) increased 27% quarter-over-quarter to $45.8 million, resulting in $13.9 million in collaboration revenue for Syndax.
• Revuforj received U.S. FDA approval on October 24, 2025, for R/R NPM1m AML, expanding its market opportunity and solidifying its leadership.
• Revuforj was included in the NCCN Guidelines for R/R NPM1m AML on September 18, 2025, enhancing its clinical adoption.
• The company maintains a strong cash position of $456.1 million, which is expected to fund operations to profitability.
• Net loss decreased to $60.7 million ($0.70/share) from $84.1 million ($0.98/share) in the prior year period, indicating improved financial efficiency.
• Revuforj is now the first and only FDA-approved therapy for both R/R AML with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation.
• Niktimvo shows rapid uptake across U.S. bone marrow transplant centers, with 90% of patients who started in Q1 remaining on treatment.
• Multiple positive data presentations for Revuforj and axatilimab are scheduled for the ASH 2025 Annual Meeting, highlighting pipeline strength.

Negatives

• The company reported a net loss of $60.7 million for the quarter, indicating continued unprofitability.
• Selling, general and administrative expenses increased significantly to $44.9 million from $31.1 million in the comparable prior year period, driven by commercial launch costs.

Risks

• Unexpected safety or efficacy data observed during preclinical or clinical trials could impact product development and approval.
• Clinical trial site activation or enrollment rates that are lower than expected may delay product development timelines.
• Changes to Revuforj's or Niktimvo's commercial availability could affect market access and revenue.
• Changes in expected or existing competition may impact market share and pricing power.
• Changes in the regulatory environment could introduce new hurdles for product approval or commercialization.
• Failure of collaborators to support or advance collaborations or product candidates could hinder pipeline progress.
• Unexpected litigation or other disputes may incur significant legal costs and distract management.
• Macroeconomic conditions (e.g., Russia-Ukraine war, inflation) could disrupt clinical trials, manufacturing, supply chain, or impair employee productivity.

Future Outlook

The company expects its operating expense base to remain stable over the next few years, and its current cash, cash equivalents, and investments, combined with anticipated product revenue and interest income, are projected to enable the company to reach profitability. Revuforj is positioned for long-term growth with increasing usage post-stem cell transplant and expansion into R/R NPM1m AML, with a total addressable market of over $5 billion in acute leukemia. Niktimvo's initial indication represents a $2 billion U.S. market opportunity, with potential for label and geographic expansion to over $5 billion. The company anticipates reporting data from the revumenib trial in R/R metastatic MSS colorectal cancer in Q1 2026 and topline data from the MAXPIRe trial for axatilimab in IPF in H2 2026, with new trials for revumenib in newly diagnosed AML expected to initiate by the end of 2025.

Management Comments

• "The third quarter was another remarkable period of commercial and pipeline execution for Syndax. Demand remained strong for Revuforj and Niktimvo with over $75 million in combined net sales for the quarter."
• "We also furthered our leadership in menin inhibition with the addition of Revuforj to the NCCN Guidelines for R/R NPM1m AML in late September followed by FDA approval in late October."
• "Our expansion into this second indication is underway and we are making great progress driving awareness and generating demand."
• "Additionally, we continue to advance the development of both Revuforj and Niktimvo in the frontline setting, further unlocking their multi-billion-dollar potential."

Industry Context

Syndax Pharmaceuticals operates in the highly competitive and rapidly evolving biopharmaceutical sector, specializing in innovative cancer therapies. The FDA approval of Revuforj for R/R NPM1m AML, coupled with its existing approval for KMT2A translocation, positions it as a leading targeted therapy in acute leukemias, addressing specific genetic mutations. This aligns with a broader industry trend towards precision medicine in oncology. The strong commercial uptake of both Revuforj and Niktimvo, particularly Niktimvo's rapid adoption in bone marrow transplant centers for chronic GVHD, indicates successful market penetration and addresses significant unmet medical needs. The company's strategic focus on advancing both drugs into frontline settings reflects an industry-wide shift to earlier intervention and maximizing therapeutic potential, aiming to capture larger market segments beyond relapsed/refractory indications.

Comparison to Industry Standards

• Revuforj is the first and only FDA-approved therapy for both R/R AML with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation, establishing a new benchmark for targeted treatment in these specific acute leukemia subtypes.
• The inclusion of revumenib in NCCN Guidelines as a category 2A recommended treatment option for R/R NPM1m AML signifies strong clinical validation and acceptance within the oncology community, comparable to other established therapies.
• The reported 94% Overall Response Rate (ORR) and 88% Complete Remission (CR) in the newly diagnosed AML cohort of the SAVE trial (revumenib + venetoclax/oral HMA) are highly competitive, potentially exceeding typical CR rates of 60-70% seen with standard intensive chemotherapy (7+3) in younger AML patients, and even lower rates in older or unfit patients.
• The 100% MRD negative CR by flow in the SAVE trial's ND cohort is a significant achievement, as minimal residual disease (MRD) negativity is a critical prognostic factor for long-term survival in AML, often associated with better outcomes than many current standard-of-care regimens.
• The long-term treatment duration and safety profile of axatilimab in R/R cGVHD, with patients remaining on therapy for a median of 2.8 years, suggests a favorable tolerability profile compared to some other immunosuppressive agents used in cGVHD, which can have significant long-term side effects limiting duration of use.

Stakeholder Impact

• Shareholders are likely to benefit from the strong revenue growth, FDA approval, reduced net loss, and clear path to profitability, potentially leading to increased share value.
• Patients with R/R NPM1m AML now have an additional FDA-approved treatment option with Revuforj, and ongoing trials aim to expand therapeutic options for other acute leukemias and chronic GVHD.
• Employees can expect continued stability and potential growth opportunities given the company's commercial success and pipeline advancements.
• Incyte, as a co-commercialization partner for Niktimvo, benefits directly from the strong sales and rapid uptake of the product, leading to increased collaboration revenue.
• Healthcare providers gain new, clinically validated treatment options for acute leukemias and chronic GVHD, supported by FDA approval and NCCN guideline inclusion.

Next Steps

• Highlight 12 revumenib abstracts, including 3 oral presentations, at the 67th American Society of Hematology (ASH) Annual Meeting.
• Showcase 11 axatilimab abstracts, including 3 oral presentations, at the 2025 ASH Annual Meeting.
• Initiate REVEAL trials, evaluating revumenib in combination with standard of care regimens in newly diagnosed acute leukemia patients, by the end of 2025.
• Complete enrollment in the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) by the end of 2025.
• Report data from the revumenib trial in R/R metastatic microsatellite stable (MSS) colorectal cancer (CRC) at a medical conference in the first quarter of 2026.
• Anticipate topline data from the MAXPIRe trial in the second half of 2026.
• Continue to advance the development of both Revuforj and Niktimvo in the frontline setting.

Key Dates

Recommendation

The company has demonstrated exceptional commercial execution with both Revuforj and Niktimvo exceeding expectations in revenue growth and prescription uptake. The recent FDA approval for Revuforj in R/R NPM1m AML significantly expands its market opportunity and solidifies its leadership in targeted AML therapies. The strong cash position, coupled with a stable expense outlook and a clear path to profitability, provides a robust financial foundation. Furthermore, the promising clinical data presented for both assets in various settings, including frontline, indicates substantial future growth potential and a strong pipeline. These factors collectively suggest a highly favorable investment outlook.

Keywords

Biopharmaceutical, Cancer Therapy, Oncology, AML, Acute Myeloid Leukemia, GVHD, Graft-versus-host disease, Revuforj, revumenib, Niktimvo, axatilimab, FDA Approval, Menin Inhibitor, CSF-1R, Clinical Trials, Financial Results, Q3 2025, Syndax, SNDX, NPM1m, KMT2Ar, IPF, Idiopathic Pulmonary Fibrosis